m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05690
 [1]
m6A modification ABHD11-AS1 ABHD11-AS1 METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA ABHD11-AS1 miR-1301-3p  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target LINC00035 (ABHD11-AS1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator LINC00035 (ABHD11-AS1) LncRNA View Details
Regulated Target hsa-miR-1301-3p View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary Mechanical experiments confirmed that METTL3 m6A dependently increased stability and expression levels of LINC00035 (ABHD11-AS1), and elevated ABHD11-AS1 sponged hsa-miR-1301-3p to upregulate HIF1AN, resulting in the downregulation of HIF-1alpha. this study firstly reported a novel METTL3/m6A/ ABHD11-AS1/miR-1301-3p/HIF1AN/HIF-1alpha signaling cascade in regulating the progression of cerebral I/R injury, and future work will focus on investigating whether the above genes can be used as biomarkers for the treatment of cerebral I/R injury by performing clinical studies.
Responsed Disease Acute ischemic stroke ICD-11: 8B11
 Disease Info 
Pathway Response Cell cycle hsa04110
Cell Process Cell apoptosis
Cell cycle
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
8B11: Acute ischemic stroke 7 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name PEG-bHb-CO Phase 2 [2]
Synonyms
Sanguinate; Oxygen transfer agent (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease); PEGylated bovine hemoglobin-carbon monoxide (trauma/cardiovascular disease), Prolong Pharmaceuticals; PEG-bHb-CO (trauma/cardiovascular disease), Prolong Pharmaceuticals
    Click to Show/Hide
External Link
TTD: D0A6LT
 Compound Name DM199 Phase 2 [3]
External Link
TTD: DS70MP
 Compound Name BIIB131 Phase 2 [4]
Synonyms
(2S)-2,5-bis[(2S,3S)-2-[(3E)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3H-pyrano[2,3-e]isoindol-8-yl]pentanoic acid; 733805-92-0; BCP33210; BIIB131; CS-0083560; GTPL12300; HY-122311; Orniplabin; SCHEMBL2624852; SMTP 7; SMTP7; SMTP7; SMTP-7; Stachybotrys microspora triprenyl phenol 7; TMS-007
    Click to Show/Hide
External Link
CID: 50898407
TTD: DEV2G0
 Compound Name BMS-986177 Phase 2 [5]
Synonyms
Milvexian; UNII-0W79NDQ608; Milvexian (USAN); Milvexian [USAN]; BMS 986177; JNJ-70033093; 1802425-99-5; CHEMBL4112929; SCHEMBL16982989; WHO 11401; D11802; (5R,9S)-9-(4-(5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxopyrimidin-1(6H)-yl)-21-(difluoromethyl)-5-methyl-21H-3-aza-1(4,2)-pyridina-2(5,4)-pyrazolacyclonaphan-4-one; (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one; 11,15-Metheno-15H-pyrazolo(4,3-b)(1,7)diazacyclotetradecin-5(6H)-one, 10-(4-(5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl)-6-oxo-1(6H)-pyrimidinyl)-1-(difluoromethyl)-1,4,7,8,9,10-hexahydro-6-methyl-, (6R,10S)-2
    Click to Show/Hide
External Link
CID: 118277544
TTD: DB6XD8
 Compound Name SonoLysis Prolyse Phase 2 [6]
External Link
TTD: D08JGE
 Compound Name ACT017 Phase 1/2 [7]
External Link
TTD: DPG5T9
 Compound Name Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 Patented [8]
Synonyms
PMID27998201-Compound-16
    Click to Show/Hide
External Link
CID: 1720818
TTD: D0UX4J
References
Ref 1 METTL3-deficiency Suppresses Neural Apoptosis to Induce Protective Effects in Cerebral I/R Injury via Inhibiting RNA m6A Modifications: A Pre-clinical and Pilot Study. Neurochem Res. 2024 Jan;49(1):85-98. doi: 10.1007/s11064-023-04015-6. Epub 2023 Aug 23.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 ClinicalTrials.gov (NCT04123613) Multiple Doses of DM199 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
Ref 4 ClinicalTrials.gov (NCT05764122) A Multicenter, Operationally Seamless, Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Intravenous BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well. U.S.National Institutes of Health.
Ref 5 ClinicalTrials.gov (NCT03766581) A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel (AXIOMATIC-SSP). U.S. National Institutes of Health.
Ref 6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004567)
Ref 7 ClinicalTrials.gov (NCT03803007) Acute Ischemic Stroke Interventional Study (ACTIMIS). U.S. National Institutes of Health.
Ref 8 Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opin Ther Pat. 2017 Jun;27(6):643-656. doi: 10.1080/13543776.2017.1272572. Epub 2016 Dec 23.